Gliomas are the primary brain tumors of the central nervous system. The prognosis, especially for high-grade gliomas, is dismal; the treatment of these tumors represents an unmet need in medicine. This book, contributed by an excellent team of clinicians and basic scientists, touches upon several critical aspects of glioma research and clinical therapies. There is a considerable emphasis on translational efforts. The 13 chapters of the book cover aspects of clinically-relevant models, glioma stem-like cells, IDH mutations, integrated approach for better patient outcome, abnormal cholesterol and other metabolic processes, bioinformatics for survival prediction, molecular signature for prognostication, neuro-functional monitoring during surgery, glioma-related epilepsy, and glioneuronal tumors along with various natural and synthetic drug candidates currently under evaluation. As such, the individual contributions provide a glimpse on the magnitude of challenges and potential solutions in a variety of research areas. This book will likely be interest to a wide audience seeking more information on challenges gliomas present to both scientists and clinicians.

Contents

• Foreword
• Preface
• List of Contributors
• 1. Pre-Clinical Models and Potential Novel Therapies for Glioblastomas
  Michelle Zalles and Rheal A. Towner.
  • INTRODUCTION
  • THERAPY-LIMITING FACTORS FOR GLIOBLASTOMAS
  • PRECLINICAL MODELS
  • PROMISING THERAPEUTICS
  • CONCLUSION
  • REFERENCES
• 2. Mouse Models of Experimental Glioblastoma
  Fang Jin, Helen J. Jin-Lee, and Aaron J. Johnson.
  • INTRODUCTION
  • MOUSE MODELS OF GLIOBLASTOMA
  • TRANSPLANT GLIOBLASTOMA MOUSE MODELS
  • CONCLUSION
  • REFERENCES
• 3. Cancer Stem Cells in Pediatric Brain Tumors
  Miranda M. Tallman, Abigail A. Zalenski, and Monica Venere.
  • INTRODUCTION
  • PEDIATRIC BRAIN TUMOR CSC PROPERTIES
  • CSCS ACROSS PEDIATRIC BRAIN TUMOR TYPES
  • DIPG CSCs
  • TARGETING PEDIATRIC CSC
  • CONCLUSION
  • REFERENCES
• 4. Emerging Roles of Wild-type and Mutant IDH1 in Growth, Metabolism and Therapeutics of Glioma
  Matthew Garrett, Yuki Fujii, Natsuki Osaka, Doshun Ito, Yoshihisa Hirota, and Atsuo T. Sasaki.
  • INTRODUCTION
  • METABOLIC CHARACTERIZATION OF WILD-TYPE IDH1 GLIOMA
  • BIOLOGICAL IMPACT OF D-2HG ON GLIOBLASTOMA
  • POTENTIAL IMPACTS OF IDH1 MUTATION ON CELLULAR METABOLISM
  • THREE POSSIBLE MODELS EXPLAIN THE APPARENTLY PARADOXICAL OUTCOMES OF IDH1 MUTATION
  • THERAPEUTIC SENSITIVITY AND RESISTANCE OF IDH MUTANT GLIOMAS
  • CONCLUSION
  • REFERENCES
• 5. Integration of Molecular Analysis, Cutting-edge Mouse Genetic Models and Proton Therapy to Improve Outcomes for Glioma Patients
  Soma Sengupta, Luke E. Pater, Daniel Pomeranz Krummel, Bruce J. Aronow, Yoshihisa Hirota, Timothy N. Phoenix, and Atsuo T. Sasaki.
  • INTRODUCTION
  • THE CURRENT STATE OF MOLECULAR ANALYSIS AND RELEVANCE IN GLIOBLASTOMA TREATMENT OPTIONS
  • EMERGING MOUSE MODELS OF PEDIATRIC AND ADULT HIGH-GRADE GLIOMA AND GLIOBLASTOMA
  • PROTON BEAM THERAPY
  • CONCLUSION
  • REFERENCES
• 6. Cholesterol Derivatives as Promising Anticancer Agents in Glioblastoma Metabolic Therapy
  Khouloud Sassi, Thomas Nury, Mohammad Samadi, Fatma Ben-Aissa Fennira, Anne Vejux, and Gérard Lizard.
  • INTRODUCTION
  • CANCER METABOLISM
  • GLIOBLASTOMA FEATURES
  • METABOLISM IN GLIOBLASTOMA
  • CURRENT GLIOBLASTOMA THERAPIES
  • THERAPIES TARGETING CHOLESTEROL METABOLISM
  • CONCLUSION
  • REFERENCES
• 7. Targeting Energy Metabolism to Overcome Therapeutic Resistance of Glioblastoma and Tumor-associated Edema
  Biplab Dasgupta, Yoshihisa Hirota, Yuki Fujii, Natsuki Osaka, Doshun Ito, David R. Plas, and Atsuo T. Sasaki.
  • INTRODUCTION
  • EMERGING ROLES OF ENERGY METABOLISM IN GLIOBLASTOMA AND THERAPEUTIC TARGETING
  • GTP METABOLIC REPROGRAMMING PROMOTES GLIOBLASTOMA MALIGNANCY
  • CONCLUSION
  • REFERENCES
• 8. Therapeutic Potential of Curcumin for the Treatment of Malignant Gliomas
  Blake C. Walker, Srijan Adhikari, and Sandeep Mittal.
  • INTRODUCTION
  • CHEMICAL AND PHYSICAL PROPERTIES OF CURCUMIN
  • TOXICITY
  • CURCUMIN AND SIGNAL CASCADE PROTEINS
  • CURCUMIN DECREASES TUMOR INVASIVENESS
  • CURCUMIN INDUCES OXIDATIVE STRESS AND APOPTOSIS IN GLIOMA CELL LINES
  • BARRIERS TO CURCUMIN AS A SYSTEMIC THERAPY
  • CONCLUSION
  • REFERENCES
• 9. Survival Prediction in Gliomas: Current State and Novel Approaches
  Rachel Zhao and Andra Valentina Krauze.
  • INTRODUCTION
  • NOVEL APPROACHES TO SURVIVAL PREDICTION IN GLIOMA
  • CONCLUSION
  • REFERENCES
• 10. Molecular Markers of Gliomas to Predict Treatment and Prognosis: Current State and Future Directions
  Catarina Rapôso, João Luiz Vitorino-Araujo, and Natália Barreto.
  • INTRODUCTION
  • MOLECULAR CHARACTERIZATION OF GLIOMAS
  • MOLECULAR PROFILE GUIDING CLINICAL PRACTICE
  • FUTURE DIRECTIONS
  • CONCLUSION
  • REFERENCES
• 11. Brain Mapping: Real-Time Neuropsychological Testing Experience during Low-Grade Tumor Resection
  Barbara Tomasino, Tamara Ius, and Miran Skrap.
  • INTRODUCTION
  • DIRECT ELECTRICAL STIMULATION
  • REAL-TIME NEUROPSYCHOLOGICAL TESTING
  • CONCLUSION
  • REFERENCES
• 12. Pathogenesis and Management of Brain Tumor-Related Epilepsy
  Srijan Adhikari, Blake C. Walker, and Sandeep Mittal.
  • INTRODUCTION
  • EPIDEMIOLOGY AND PATHOGENESIS
  • CLINICAL PRESENTATION
  • MEDICAL MANAGEMENT OF BTRE
  • CONCLUSION
  • REFERENCES
• 13. Glioneuronal Tumors: Insights into a Rare Tumor Entity
  Andra Valentina Krauze.
  • INTRODUCTION
  • CLINICAL PRESENTATION
  • MANAGEMENT, CLINICAL RESPONSE AND LATE EFFECTS
  • CONCLUSION
  • REFERENCES

Gliomas

ISBN: 978-0-6450017-4-7

DOI: https://doi.org/10.36255/exonpublications.gliomas.2021

Edited by

Waldemar Debinski, MD, PhD, Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston Salem, NC, USA

Published by

Exon Publications, Brisbane, Australia

Copyright© 2021 Exon Publications

Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). https://creativecommons.org/licenses/by-nc/4.0/. Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The book in its entirety is subject to copyright by the publisher. The reproduction, modification, replication and display of the book in its entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.

Notice to the user

The views and opinions expressed in this book are believed to be accurate at the time of publication. The publisher, editors or authors cannot be held responsible or liable for any errors, omissions or consequences arising from the use of the information contained in this book. The publisher makes no warranty, implicit or explicit, with respect to the contents of this book, or its use.

First Published in April 2021

Printed in Australia